07:34 AM EDT, 05/28/2024 (MT Newswires) -- Merck ( MRK ) said Tuesday that a phase 3 trial evaluating Keytruda in combination with chemotherapy as a treatment for patients with high-risk early-stage triple-negative breast cancer met its overall survival endpoint.

The trial evaluated the combination therapy as a pre-operative treatment and as a single agent after surgery, Merck ( MRK ) said. Interim analysis of the trial's data demonstrated "statistically significant and clinically meaningful improvement" in overall survival with Keytruda, along with a safety profile consistent with previous studies, Merck ( MRK ) added.

The trial enrolled 1,174 patients, the company said.

Price: 130.11, Change: +0.62, Percent Change: +0.48